KBC Group
CLDX icon

KBC Group’s Celldex Therapeutics CLDX Stock Holding History

KBC Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90K Hold
2,411
– – ﹤0.01% 1480
2026
Q1 		$76K Hold
2,411
– – ﹤0.01% 1475
2025
Q4 		$65K Hold
2,411
– – ﹤0.01% 1532
2025
Q3 		$62K Hold
2,411
– – ﹤0.01% 1559
2025
Q2 		$49K Sell
2,411
-1,317
-35% -$25.6K ﹤0.01% 1613
2025
Q1 		$68K Hold
3,728
– – ﹤0.01% 1689
2024
Q4 		$94K Buy
3,728
+1,647
+79% +$44.7K ﹤0.01% 1598
2024
Q3 		$71K Buy
2,081
+495
+31% +$18.9K ﹤0.01% 1508
2024
Q2 		$59K Hold
1,586
– – ﹤0.01% 1517
2024
Q1 		$67K Buy
+1,586
New +$65.1K ﹤0.01% 1356

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KBC Group's CLDX Position: Q2 2026 in Review

KBC Group held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 2,411 shares worth $90K. The position accounts for ﹤0.01% of the portfolio, ranked #1480.

KBC Group first reported a position in CLDX in Q1 2024 and has held it in 10 quarters since. The position peaked at $94K in Q4 2024. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • KBC Group held 2,411 shares of Celldex Therapeutics worth $90K as of Q2 2026.
  • KBC Group left its Celldex Therapeutics share count unchanged in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1480 holding.
  • KBC Group first reported a position in Celldex Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • KBC Group's Celldex Therapeutics position peaked at $94K in Q4 2024.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.